German version English version

#RETHINK HEALTH

With an ageing population, increasing life expectancy and exploding health costs, it is time to rethink. FUTRUE is the incubator for tomorrow's trends. With now more than 20 companies and over 70 drug approvals, we are active in areas such as intelligent bacteria, innovative pain therapies, chemical-free drugs, medical cannabis, dermaceuticals, functional food and e-health. Many of our companies are among the fastest growing healthcare companies in Europe. In doing so, we rely on a new generation of dynamic talents who have the courage to take unusual paths.
  • Employer of a new generation of dynamic talents

  • Incubator of global trends and innovations in healthcare

  • Accelerator with national and international structures

FUTRUE now comprises over 20 companies active in areas such as intelligent bacteria, innovative pain therapies, chemical-free drugs, medical cannabis, dermaceuticals, functional food and e-health. A selection of our companies at a glance:

Synformulas EN

Synformulas EN

Synformulas is a leading global probiotics company focused on the discovery of intelligent bacteria and the commercialization of innovative therapies for gastrointestinal diseases.

Pharma SGP EN

Pharma SGP EN

PharmaSGP concentrates on the development and distribution of chemical-free drugs with a focus on pain therapy. Already awarded the title Best OTC Company of the Year in 2015, it is one of the fastest growing pharmaceutical companies in Europe.

Remitan EN

Remitan EN

The dermaceutical company Remitan is one of Europe's leading suppliers of drinkable collagen. As an innovator in the field of dermaceuticals, the company also stands for special products, including the treatment of couperose and pigment spots.

Cannaverum EN

Cannaverum EN

The company focuses on research into innovative cannabis drugs for the treatment of neuropathic pain, tumor pain and chronic inflammatory gastrointestinal diseases.

E-Health EN

E-Health EN

E-Health is one of the absolute pioneers in the digitization of all healthcare services and processes. Telehealth, consumer health, informatics or artificial intelligence in prevention and therapy are just a few of the company's approaches, which will cover most of the location-independent everyday healthcare activities in the future.

EMCM EN

EMCM EN

EMCM is an international media agency mainly working for numerous FUTRUE companies and is one of the leading healthcare media agencies with an annual turnover of 300 million euros (gross volume). In addition to the proven media-channels print and TV, social media channels such as Facebook, Instagram and YouTube are increasingly being used.

PRODUCTS

FUTRUE has more than 70 drug approvals across the Group as well as a large number of medical and functional food products. Numerous products are currently undergoing approval procedures or clinical trials. Below you can see a selection of our leading preparations at a glance:

Kijimea EN

Kijimea EN

The medical product Kijimea Reizdarm is the most widely used medical product worldwide for the treatment of irritable bowel syndrome and its symptoms. It contains the unique and patented bacterial strain B. bifidum MIMBb75, which spreads like a plaster over the intestinal barrier damaged by irritable bowel syndrome. As a result, the damaged intestinal barrier can regenerate and irritable bowel symptoms are significantly reduced.

LHL EN

LHL EN

Cannabis Voll-Extrakt LHL is a unique cannabis extract containing more than 100 terpenes as well as the two therapeutically active cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). Canabis Full Extract LHL is used as a prescription drug for the treatment of patients with severe neuropathic pain and for the treatment of pain in tumor patients. Due to its extremely low THC concentration, the usual side effects of cannabis extracts are reduced to a minimum.

Fulminan EN

Fulminan EN

The secret of the collagen drink Fulminan's success is its unique collagen peptides. In contrast to collagen in creams, these special collagen peptides work in the deep layers of the skin due to their low molecular weight, filling up the collagen fibres. Their effectiveness has been confirmed in several studies.

Rubaxx EN

Rubaxx EN

The chemical-free Rubaxx drops are the best-selling OTC drug for the treatment of rheumatic pain in bones, tendons and muscles in Germany. Depending on the intensity of the pain, the droplet shape allows individual dosage. As a chemical-free alternative to chemical painkillers, Rubaxx has no known serious side effects or interactions.

Regularis EN

Regularis EN

The innovative medical device Kjimea Regularis was specially developed for the treatment of constipation, sluggish digestion and a bloating stomach. It contains the unique Synformularis2 fibre-complex which, thanks to its special structure, swells in the intestine and gently stretches the intestinal muscles. This gives the intestinal muscles the impulse to move normally again - the intestine gets going again on its own. Kijimea Regularis activates the intestinal activity in a natural way without interfering with the metabolism.

Restaxil EN

Restaxil EN

The most successful new product launch 2017 in the entire OTC market in Germany: Restaxil Arzneitropfen! Not without reason, because Restaxil works differently than conventional pain killers. It was developed especially for the treatment of nerve pain and offers effective pain relief for nerve pain in the back or discomfort such as tingling, burning legs. Restaxil has no known serious side effects or interactions.

MILESTONES

2008 Sale of the e-detailing platform 123MID to Novartis
2008 Sale of physician evaluation platform Docya to Novartis
2011 Launch of the blockbuster Kijimea Reizdarm (Synformulas)
2013 Sale of Lactostop (Naturwohl Vertrieb) to Dermapharm
2014 Launch of the blockbuster Rubaxx (PharmaSGP)
2015 Presence in all major European and North American markets
2015 Sale of diet blockbuster Yokebe (Naturwohl Pharma) to Perrigo
2015 PharmaSGP awarded best OTC company of the year
2017 Most successful OTC launch of the year: Restaxil (PharmaSGP)

MANAGEMENT

Clemens Fischer EN

Clemens Fischer EN

Dr. Clemens Fischer
Founder and Chief Executive Officer

 

In 2007, the doctor of medicine, business economist and MBA graduate of Harvard University founded FUTRUE GmbH (formerly 7 Investment GmbH). He discovered his enthusiasm for companies at the age of 17 when he laid the foundation for his own mobile phone company. Since then, the serial entrepreneur has founded numerous companies with FUTRUE, some of which he, after successful market positioning, sold to pharmaceutical giants such as Novartis, Dermapharm and Perrigo. Before founding FUTRUE, Clemens Fischer worked for Novartis, where he was responsible for strategy and cardiovascular affairs as a member of the German Executive Board.

Madlena Hohlefelder EN

Madlena Hohlefelder EN

Madlena Hohlefelder
Co-Founder and Chief Strategy Officer

 

The attorney left her hometown Bonn after graduating from high school to study economics at the HSG in St. Gallen, Switzerland. At the same time, she also studied law at the LMU in Munich. Since her school days, however, a career as an entrepreneur and the founding of her own company had been her dream. Before joining FUTRUE, Madlena Hohlefelder worked as a consultant for one of the largest international management consultancies, the Boston Consulting Group, in the consumer goods and energy sectors.

Natalie Weigand EN

Natalie Weigand EN

Natalie Weigand
Chief Executive Manager and Member of the Management Board PharmaSGP GmbH

 

In January 2013, Natalie Weigand joined PharmaSGP as a marketing agent. She was responsible for the Lactostop and Yokebe brands, which were successfully sold in 2014 and 2015. She also launched all successful PharmaSGP drug brands and build the team and current corporate structure together with Clemens and Madlena. Today, Natalie is responsible for the operational business as well as the strategic expansion of the product portfolio for Germany and abroad. After studying business administration, Natalie began her career at Johnson & Johnson in 2005. There she first worked in national product marketing in Germany and then moved to the European headquarters in London in 2007.

Your Career at Futrue starts here

Jobs